STOCK TITAN

PharmaTher Holdings (PHRRF) Stock News, Feb-Jul 2026

PHRRF OTC

PharmaTher Holdings Ltd. develops specialty pharmaceutical platforms centered on microneedle drug delivery. Company updates focus on PharmaPatch™ product programs for ketamine, psychedelics, GLP-1 drugs and therapeutic peptides, along with PatchPrint™, its automated tabletop microneedle patch 3D printer designed to support end-to-end patch manufacturing.

Recurring news themes include U.S. patent applications for patch manufacturing and peptide formulations, expansion of the PharmaPatch™ platform into new drug categories, regulatory and policy developments affecting ketamine, psychedelics and peptides, and the company's retained economic participation tied to its previously approved and sold U.S. generic ketamine ANDA.

Rhea-AI Summary

PharmaTher (OTCQB: PHRRF) announced a strategic focus on personalized medicines in peptides and psychedelics, built around its MEDBOTX™ robotic 3D-printing and AI formulation platform. The company aims to enable patient-specific dosing, controlled-release profiles, and multiple dosage formats such as tablets, films, gels, and patches.

PharmaTher highlights upcoming FDA Pharmacy Compounding Advisory Committee discussions on peptide bulk substances and recent FDA guidance on psychedelic clinical studies as potential enablers of compliant development. The company plans a capital‑efficient commercialization model including proprietary formulations, partnerships with 503A pharmacies, hospitals, research institutions, pharma and biotech firms, and supplying MEDBOTX™ systems and consumables.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.93%
Tags
none
-
Rhea-AI Summary

PharmaTher (OTCQB:PHRRF) is shifting its core platform from PatchPrint to MEDBOTX, a robotic 3D printing system for personalized medicines, peptides and advanced dose formats. MEDBOTX targets point-of-care and small-batch manufacturing in hospitals, compounding pharmacies, research institutions and partner settings.

The company plans commercial readiness in summer–fall 2026, with a focus on regulated peptides, compounded pharmaceuticals, consumables-based recurring revenue and CDMO-style formulation services.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.57%
Tags
none
-
Rhea-AI Summary

PharmaTher (OTCQB:PHRRF) announced that Sairiyo Therapeutics, 49% owned by PharmaTher, is advancing its patented oral cepharanthine formulation PD-001 as a potential candidate for Hantavirus-related diseases.

Independent research found cepharanthine inhibited Hantavirus pseudovirus infection in mice by about 92–94% at 45–180 mg/kg/day. PD-001 has Australian ethics approval for a first-in-human Phase 1 trial in healthy volunteers to assess safety and pharmacokinetics only. PharmaTher emphasizes PD-001 is not proven to treat or prevent Hantavirus or any infectious disease, and future development depends on Phase 1 results, further data, regulatory review, financing, and manufacturing readiness.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.93%
Tags
none
Rhea-AI Summary

PharmaTher (OTCQB: PHRRF) says a U.S. executive order on accelerating treatments for serious mental illness (April 18, 2026) could create a more supportive regulatory backdrop for its ketamine programs. The company highlights its KetaVault partnership portal, a completed IND‑enabling PK/tolerability study for a ketamine microneedle patch, retained ketamine programs, and ongoing upside from a prior FDA‑approved ketamine ANDA sale that may generate more than US$25 million over time, subject to commercial performance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
none
-
Rhea-AI Summary

PharmaTher (OTCQB: PHRRF) says its PatchPrint™ automated microneedle manufacturing platform and PharmaPatch™ product platform could benefit from two U.S. regulatory shifts: a presidential executive order accelerating psychedelic treatments and an FDA/HHS move to reclassify therapeutic peptides with an advisory meeting on July 23–24, 2026.

The company highlights completed IND‑enabling work for a ketamine patch, provisional U.S. patent filings for peptide candidates and PatchPrint™, and potential commercial pathways for compounding pharmacies and hospitals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
49.30%
Tags
none
-
Rhea-AI Summary

PharmaTher (OTCQB: PHRRF) supports a proposed U.S. peptide reclassification and links the potential policy change to increased commercial relevance for its PharmaPatch microneedle delivery and PatchPrint manufacturing platform.

The company notes the FDA's July 23-24, 2026 Pharmacy Compounding Advisory Committee agenda lists BPC-157, KPV and TB-500—peptides already on PharmaTher's roadmap—and cites a provisional patent filed April 13, 2026 for stabilized peptide formulations for microneedle delivery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.32%
Tags
none
Rhea-AI Summary

PharmaTher (OTCQB: PHRRF) filed U.S. provisional patent application No. 64/034,315 on April 13, 2026 for "Stabilized Peptide Compositions for Microneedle and Transdermal Delivery." The filing aims to protect formulation approaches to improve peptide stability, shelf life, manufacturing compatibility and layered microneedle designs for PharmaPatch while complementing PatchPrint manufacturing.

Claims include polymers, sugars, amino acids, buffers, layered tip/backing designs, low-moisture packaging, and support for multiple peptide categories and combined-peptide dosage forms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.04%
Tags
none
-
Rhea-AI Summary

PharmaTher (OTCQB: PHRRF) filed a provisional USPTO patent (Application No. 64/015,408) on March 26, 2026 for PatchPrint, an automated tabletop microneedle patch 3D printer that integrates dispensing, vacuum loading, drying, demolding and packaging.

The company is pursuing commercialization, engineering partnerships, peptide patch development, branded wellness products and partner-facing manufacturing services to scale its PharmaPatch programs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.78%
Tags
none
-
Rhea-AI Summary

PharmaTher (OTCQB: PHRRF) announced a strategic initiative on March 3, 2026 to expand its PharmaPatch™ microneedle platform into select therapeutic peptides for the U.S. market.

The company cited prior ketamine, psychedelics and GLP-1 patch work, named initial candidates (BPC-157, GHK-Cu, TB-500, KPV), referenced a large U.S. peptide market (US$65.1B 2024 to ~US$160.3B by 2030, 14.7% CAGR), and noted staged R&D, regulatory monitoring, and investigational status with no FDA approvals.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.54%
Tags
none
Rhea-AI Summary

PharmaTher (OTCQB: PHRRF) announced a strategic initiative to seek Health Canada approval for generic semaglutide and, if approved, commercialize in Canada. Regulatory exclusivity expired in January 2026, opening a pathway for generics. The plan targets Health Canada approval in 2026 with broad dose coverage (0.25 mg–2.4 mg) and a sterile injectable manufacturing strategy audited by regulators. The company cites prior U.S. FDA approval and monetization of ketamine rights with potential proceeds exceeding US$25 million, and notes Ozempic generated an estimated C$2.9 billion in Canadian sales in 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.94%
Tags
none

FAQ

What is the current stock price of PharmaTher Holdings (PHRRF)?

PharmaTher Holdings (PHRRF) last closed at $0.0353.

What is the market cap of PharmaTher Holdings (PHRRF)?

The market cap of PharmaTher Holdings (PHRRF) is approximately $3.2M.